___

• 1) Stolze H1, Klebe S, Zechlin C, Baecker C, Friege L, Deuschl G. Falls in frequent neurological diseases--prevalence, risk factors and aetiology. J Neurol. 2004;251:79-84.2) Thurman DJ1, Stevens JA, Rao JK; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: Assessing patients in a neurology practice for risk of falls (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2008;70(6):473-93) Tinetti ME, Williams TF, Mayewski R, Fall Risk Index for elderly patients based on number of chronic disabilities. Am J Med 1986:80:429-4344) Fasano A, Canning CG, Hausdorff JM, Lord S, Rochester L. Falls in Parkinson's disease: A complex and evolving picture. Mov Disord. 2017;32:1524-1536.5) Hiorth YH, Alves G, Larsen JP, Schulz J, Tysnes OB, Pedersen KF. Long-term risk of falls in an incident Parkinson's disease cohort: the Norwegian ParkWest study. J Neurol. 2017;264:364-372.6) Critchley RJ, Khan SK, Yarnall AJ, Parker MJ, Deehan DJ. Occurrence, management and outcomes of hip fractures in patients with Parkinson's disease. Br Med Bull. 2015;115:135-42. 7) Almeida LRS, Valenca GT, Negreiros NN, Pinto EB, Oliveira-Filho J. Predictors of Recurrent Falls in People with Parkinson's Disease and Proposal for a Predictive Tool. J Parkinsons Dis. 2017;7:313-324. 8) Bohnen NI, Müller ML, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, Albin RL. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009;73:1670-6.9) Allcock LM, Rowan EN, Steen IN, Wesnes K, Kenny RA, Burn DJ. Impaired attention predicts falling in Parkinson's disease. Parkinsonism Relat Disord. 2009;15:110-5.10) Allen NE, Sherrington C, Paul SS, Canning CG. Balance and falls in Parkinson's disease: a meta-analysis of the effect of exercise and motor training. Mov Disord. 2011;26:1605-15. 11) Chung KA, Lobb BM, Nutt JG, Horak FB. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology. 2010;75:1263-9.12) Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JC, Whone AL, Ben-Shlomo Y. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:249-58.